Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LIFELINE SCIENTIFIC INC. We currently have 11 research reports from 1 professional analysts.
|08Dec16 04:58||RNS||CLOSING OF THE MERGER - CANCELLATION FROM AIM|
|10Nov16 07:00||RNS||Date of merger closing and cancellation|
|06Oct16 03:18||RNS||RESULTS OF SPECIAL MEETING|
|26Sep16 07:00||RNS||Half-year Report|
|14Sep16 05:13||RNS||Publication of Proxy Statement & Notice of Meeting|
|02Sep16 07:01||RNS||Recommended Cash Acquisition|
|02Sep16 07:00||RNS||Trading update|
Frequency of research reports
Research reports on
LIFELINE SCIENTIFIC INC
LIFELINE SCIENTIFIC INC
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Panmure Morning Note 26-09-2016
26 Sep 16
Following the company’s statement on 2 September 2016 (recommended cash acquisition, trading update) the company has issued interim results this morning. Given the ongoing process set in train following the announcement of the definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) (02 September 2016) we retain our recommendation and forecasts Under Review.
Panmure Morning Note 02-09-2016
02 Sep 16
This morning Lifeline Scientific has announced it has entered into a definitive merger agreement with Shanghai Genext Medical Technology Co. Ltd (SGM) and, separately, released a trading update for the 6 months ending 30 June 2016. The cash offer from SGM values Lifeline Scientific at circa $87.8m or $4.083 in cash per share. If approved the transaction is expected to close in the fourth quarter calendar 2016 and by no later than 9 December 2016. We remind investors that LSI is incorporated in the State of Delaware in the USA and the merger is proposed in accordance with the Delaware General Corporation Law. The acquisition is not subject to the UK City Code on Takeovers and Mergers and is subject to shareholder approval. We retain our recommendation and forecasts Under Review.
Panmure Morning Note 27-4-2016
27 Apr 16
FY15 headline numbers were highlighted in January’s trading update: revenues $39.4m, operating profit $5.7m (2014: $2.4m). Year-end cash $6.9m – company is now debt free having paid off revolver balance of $2.2m by year-end. Strategic review – company is in discussions with interested parties, which may or may not lead to an offer. Usual caveats on outcomes and timing apply, but given the Board expects to provide a further update by end June, we assume Lifeline is probably quite deep into the process and this looks like the lead in terms of possible strategic options.
Panmure Morning Note 19-01-16
19 Jan 16
Further to Lifeline's ahead-of-expectations trading update and announced stocking order ($3.3m) from its principal distributor in China (18 December 2015), the company has today released further detail on the year ending 31 December 2015. While the strategic and financial review announced on 21 September 2015 is still ongoing, strong operational progress is clearly being delivered and the confident tone of the statement is well-deserved. Prelims are expected by the end of April 2016.
Panmure Morning Note 18-12-15
18 Dec 15
This morning Lifeline Scientific announces an update on trading, in advance of a more detailed update scheduled for February, and the receipt of a stocking order from its principal distributor in China worth approximately US$3.3m. The company also announces that it expects revenues for the year ending 31 December 2015 to be ahead of expectations and for adjusted pre-tax profit to be materially ahead of market expectations. A further trading update will be provided in January.
19 Jan 17
Aggregated Micro Power* (AMPH): Funding for first peaking power plant project (CORP) | The Mission Marketing Group* (TMMG): Positive trading update (CORP) | Cello (CLL): Increasingly backed by, and leveraging, technology (BUY) | 4imprint (FOUR): Growth backed by strong cash flow continues (BUY) | Allergy Therapeutics (AGY): Positive trading update and market share gains drive upgrades (BUY) | Shanta Gold (SHG): Q4 operating results (BUY) | Sound Energy (SOU): Tendrara extended well test result (BUY) | Revolution Bars (RBG): Price target increase (BUY)
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare
Demanding targets exceeded
17 Jan 17
Sinclair is a pure-play aesthetics company with a concentrated and highly competitive portfolio of differentiated injectable aesthetics products, which target unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments, which is a significant growth opportunity. Sinclair has an established sales and marketing presence in Europe, direct sales in Brazil, and operates through an international group of distributors in other markets, including SE Asia and the US. With the benefit of a strong balance sheet, Sinclair is investing in an accelerated growth phase and margin expansion.
What a year it was!
16 Jan 17
2016 got off to a rocky start. Not long into January, after just a few trading days, global equity markets lost more than US$4tn of value due to investor sentiment towards China’s economic slowdown and depreciating currency. This was immediately followed by a slump in the oil price. By the third week of January, Brent Crude hit its year low at $27.10 a barrel causing an immediate sell off in the energy sector. Once the Q1 dust had settled, attention turned to the UK’s vote on whether to remain a member of the EU. The Brexit vote result proved to be a genuine shock for markets, with many investors having believed that the UK would stay within the European Union. Attention soon turned to the equally ill-tempered US Presidential elections and all the political and economic unknowns that Trump’s victory has spawned. As a result, AIM, has seen a roller-coaster of a year in 2016.